UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 27, 2006
BIOMET, INC.
(Exact name of registrant as specified in its charter)
Indiana 0-12515 35-1418342
------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
56 East Bell Drive
Warsaw, Indiana 46582
--------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (574) 267-6639
--------------
Not Applicable
---------------
(Former name or former address,
if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
Biomet, Inc. (the "Company") hosted a conference call with the public on March
27, 2006, during which the Company presented information regarding the
retirement of Dane A. Miller, its President and Chief Executive Officer. He
was replaced by Daniel P. Hann, 50, the Company's general counsel and member
of the board, on an interim basis as the Company searches for a successor.
Pursuant to Regulation FD, this report is being filed for the purpose of
furnishing to the Securities and Exchange Commission the Conference Call
Transcript, a copy of which is attached hereto as Exhibit 99.1.
The information, including Exhibit 99.1, in this Form 8-K is being furnished
and shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section.
The information in this Form 8-K shall not be incorporated by reference into
any filing under the Securities Act of 1933, except as shall otherwise be
expressly set forth by specific reference in such filing.
The information, including Exhibit 99.1, in this Form 8-K contains certain
statements that are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, as amended. Although the Company believes that the assumptions,
on which the forward-looking statements contained herein are based, are
reasonable, any of those assumptions could prove to be inaccurate given the
inherent uncertainties as to the occurrence or non-occurrence of future
events. There can be no assurance that the forward-looking statements
contained in this Form 8-K will prove to be accurate. Some of the factors that
could cause actual results to differ from those contained in forward-looking
statements made in this Form 8-K include the success of the Company's
principal product lines and reorganization efforts with respect to its EBI
operations, the Company's ability to develop and market new products and
technologies in a timely manner, government regulation, currency exchange rate
fluctuations, reimbursements from third party payors, litigation, revenue and
earnings estimates, and other risk factors as set forth from time to time in
the Company's filings with the Securities and Exchange Commission. The
inclusion of a forward-looking statement herein should not be regarded as a
representation by the Company that the Company's objectives will be achieved.
The Company undertakes no obligation to publicly update forward-looking
statements, whether as a result of new information, future events or
otherwise.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1 Conference Call Transcript
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOMET, INC.
Date: March 27, 2006 By: /s/ Daniel P. Hann
-----------------------
Name: Daniel P. Hann
Title: Interim President and
Chief Executive Officer
Exhibit Index
Exhibit 99.1 Conference Call Transcript